Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cell Cycle. 2005 Apr;4(4):549-51. Epub 2005 Apr 28.

Histone deacetylase inhibitors in programmed cell death and cancer therapy.

Author information

  • 1Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. marksp@mskcc.org

Abstract

Histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), are targeted anticancer agents that have significant anticancer activity at doses well tolerated by patients. Recently, we found that HDAC inhibitors can trigger both mitochondria-mediated apoptosis and caspase-independent autophagic cell death, indicating potential benefit of HDAC inhibitors in treating cancers with apoptotic defects. We also found that thioredoxin (TRX) might play a significant role in HDAC inhibitor-induced cell death, and HDAC inhibitors increase TRX levels in normal cells but not transformed cells, which is likely to be one of the reasons why HDAC inhibitors preferentially kill cancer cells. In this review, we discuss the study of HDAC inhibitors in cell death and cancer research, the implications of our recent findings, and some outstanding questions that need to be addressed.

PMID:
15738652
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk